



MEDICAL POLICY STATEMENT

Ohio Medicaid

Policy Name & Number	Date Effective
Hypoglossal Nerve Stimulation for the Treatment of Obstructive Sleep Apnea-OH MCD-MM-1253	03/01/2025-08/31/2025
Policy Type	
MEDICAL	

Medical Policy Statement prepared by CareSource and its affiliates are derived from literature based on and supported by clinical guidelines, nationally recognized utilization and technology assessment guidelines, other medical management industry standards, and published MCO clinical policy guidelines. Medically necessary services include, but are not limited to, those health care services or supplies that are proper and necessary for the diagnosis or treatment of disease, illness, or injury and without which the patient can be expected to suffer prolonged, increased or new morbidity, impairment of function, dysfunction of a body organ or part, or significant pain and discomfort. These services meet the standards of good medical practice in the local area, are the lowest cost alternative, and are not provided mainly for the convenience of the member or provider. Medically necessary services also include those services defined in any Evidence of Coverage documents, Medical Policy Statements, Provider Manuals, Member Handbooks, and/or other policies and procedures.

Medical Policy Statements prepared by CareSource and its affiliates do not ensure an authorization or payment of services. Please refer to the plan contract (often referred to as the Evidence of Coverage) for the service(s) referenced in the Medical Policy Statement. If there is a conflict between the Medical Policy Statement and the plan contract (i.e., Evidence of Coverage), then the plan contract (i.e., Evidence of Coverage) will be the controlling document used to make the determination. According to the rules of Mental Health Parity Addiction Equity Act (MHPAEA), coverage for the diagnosis and treatment of a behavioral health disorder will not be subject to any limitations that are less favorable than the limitations that apply to medical conditions as covered under this policy.

Table of Contents

A. Subject.....	2
B. Background.....	2
C. Definitions	2
D. Policy	3
E. Conditions of Coverage.....	4
F. Related Policies/Rules	4
G. Review/Revision History.....	5
H. References	5

A. Subject

Hypoglossal Nerve Stimulation for the Treatment of Obstructive Sleep Apnea

B. Background

Obstructive Sleep Apnea (OSA) is a chronic disorder characterized by recurrent episodes of upper airway obstruction during sleep. The untreated disruption of airflow caused by OSA is associated with multiple comorbidities, such as nocturnal hypoxemia, cardiac arrhythmia, hypertension, an increased risk of cardiovascular disease, cessation of breathing, loud snoring, and daytime sleepiness. Continuous positive airway pressure (CPAP) therapy, which delivers oxygen in a continuous stream independent of whether the patient is inhaling or exhaling a breath, has been the mainstay therapy for treatment of OSA. However, despite its efficacy and manufacturers' redesigns to make the devices more comfortable, a large percentage of patients are unable to tolerate CPAP therapy, and adherence is low. As a result, alternative treatment strategies are necessary.

The hypoglossal nerve is the twelfth cranial nerve and innervates all the extrinsic and intrinsic muscles of the tongue, except for the palatoglossus, which is innervated by the vagus nerve. It is a nerve with a solely motor function. The nerve arises from the hypoglossal nucleus in the brain stem as a number of small rootlets, passes through the hypoglossal canal and down through the neck, and eventually passes up again over the tongue muscles it supplies into the tongue. There are two hypoglossal nerves in the body: one on the left and one on the right.

The hypoglossal nerve stimulator (HGNS) is an implanted medical device that works to reduce the occurrence of OSA by electrically stimulating the hypoglossal nerve to the tongue. A surgeon implants the system containing a neurostimulator subcutaneously in the patient's upper right chest, with one lead attached to the patient's hypoglossal nerve (cranial nerve XII) at the base of the tongue. The lead in the chest consists of a pressure sensor that detects breathing. Information about respiration rate is relayed to the device, which stimulates the hypoglossal nerve in the tongue. When stimulated, the tongue moves forward, opening the airway. The patient can operate the device by remote control, which the patient activates before going to sleep. The device turns on after 20 minutes to minimize disrupting the patient's sleep onset. The device must be manually turned off via remote when the patient wakes.

C. Definitions

- **Apnea-Hypopnea Index (AHI)** – The number of respiratory events (apneas, hypopneas) divided by the number of hours of sleep documented during a PSG or other sleep study.
- **Drug Induced Sleep Endoscopy (DISE)** – A diagnostic tool to assess the upper airway of snorers and OSA patients in conditions that mimic natural sleep. Due to documented inconsistency in determining if complete concentric collapse (CCC) is present, the inserting provider shall be certified by the FDA-approved manufacturer's second opinion service of validation via video clip submissions of at least 80%

agreement in at least 15 consecutive studies. Inserting providers shall have documentation to submit to this contractor if requested.

- **Hypoglossal Nerve** – The twelfth cranial nerve that stimulates all the extrinsic and intrinsic muscles of the tongue, except for the palatoglossus, which is stimulated by the vagus nerve.
- **Obstructive Sleep Apnea (OSA)** – A disease characterized by recurrent episodes of upper airway obstruction during sleep.
- **Polysomnography (PSG)** – The gold standard lab test used to diagnose obstructive sleep apnea.

D. Policy

- I. CareSource considers HGNS for the treatment of moderate to severe OSA medically necessary when **ALL** the following clinical criteria are met:
 - A. A pulmonary specialist, internal medicine provider, or sleep medicine specialist verifies the member is eligible for treatment.
 - B. If the member has a cardiac condition, this requires clearance from a cardiologist.
 - C. The member is 18 years of age or older.
 - D. Body mass index (BMI) is less than 35 kg/m².
 - E. An in-lab (eg, PSG) or home sleep study has been performed no more than 24 months before the first consultation of the HGNS implant, and there has not been a change of body weight by 10% or more from the time of the diagnostic sleep study.
 - F. Member has predominantly obstructive events (defined as central and mixed apneas less than 25% of the total AHI).
 - G. AHI is 15 to 65 events per hour.
 - H. Member has documentation that demonstrates bilevel positive airway pressure (BiPAP) or CPAP failure:
 1. defined as AHI greater than 15 despite BiPAP or CPAP usage
 2. BiPAP or CPAP intolerance (defined as less than 4 hours per night, 5 nights per week or the BiPAP or CPAP has been returned)
 3. shared decision making that the patient was intolerant of BiPAP or CPAP in consultation with a sleep expert
 - I. Complete concentric collapse at the soft palate level is absent on a DISE procedure.
 - J. There are no other anatomical findings that would compromise performance of device (eg, tonsil size 3 or 4 per standardized tonsillar hypertrophy grading scale).
- II. CareSource considers the following not medically necessary and, therefore, not covered:
 - A. HGNS is considered not medically reasonable and necessary for all other indications.

The MEDICAL Policy Statement detailed above has received due consideration as defined in the MEDICAL Policy Statement Policy and is approved.

- B. Non-FDA-approved HGNS is considered not medically reasonable and necessary for the treatment of adult OSA due to insufficient evidence of safety and efficacy.
- C. HGNS is considered not medically reasonable and necessary when **ANY** of the following contraindications are present:
 - 1. members with central and mixed apneas that make up more than one-quarter of the total AHI
 - 2. members with an implantable device could experience unintended interaction with the HGNS implant system
 - 3. BMI equal to or greater than 35
 - 4. neuromuscular disease
 - 5. hypoglossal-nerve palsy
 - 6. severe restrictive or obstructive pulmonary disease
 - 7. moderate-to-severe pulmonary arterial hypertension
 - 8. severe valvular heart disease
 - 9. New York Heart Association Class III or IV heart failure
 - 10. recent myocardial infarction or severe cardiac arrhythmias (within the past 6 months)
 - 11. persistent uncontrolled hypertension despite medication use
 - 12. an active, serious mental illness that reduces the ability to carry out Activities of Daily Living (ADLs) and interferes with the ability to operate the HGNS and report problems to the attending provider
 - 13. coexisting non-respiratory sleep disorders that would confound functional sleep assessment
 - 14. members who are, or who plan to become pregnant
 - 15. members requiring Magnetic Resonance Imaging (MRI) with Inspire model 3024
 - 16. members requiring MRI with Inspire model 3028, can undergo MRI on the head and extremities if certain conditions and precautions are met (refer to the manufacturer guidelines for this model and future models for more information)
 - 17. members unable or without the necessary assistance to operate the sleep remote
 - 18. members with any condition or procedure that has compromised neurological control of the upper airway
- E. Conditions of Coverage
N/A
- F. Related Policies/Rules
N/A

The MEDICAL Policy Statement detailed above has received due consideration as defined in the MEDICAL Policy Statement Policy and is approved.

G. Review/Revision History

DATE		ACTION
Date Issued	02/16/2022	New Policy
Date Revised	02/15/2023	Lowered age to 18 to make less restrictive. Added BiPAP.
	02/14/2024	Annual review: editorial changes to policy document, added definitions, and updated references. Approved at Committee.
	12/04/2024	Annual review: updated references. Approved at Committee.
Date Effective	03/01/2025	
Date Archived	08/31/2025	This Policy is no longer active and has been archived. Please note that there could be other Policies that may have some of the same rules incorporated and CareSource reserves the right to follow CMS/State/NCCI guidelines without a formal documented Policy.

H. References

1. Baptista PM, Costantino A, Moffa A, et al. Hypoglossal nerve stimulation in the treatment of obstructive sleep apnea: patient selection and new perspectives. *Nat Sci Sleep*. 2020;12:151-159. doi:10.2147/NSS.S221542
2. Chang JL, Goldberg AN, Alt JA, et al. International consensus statement on obstructive sleep apnea. *Int Forum Allergy Rhinol*. 2023;13(7):1061-1482. doi:10.1002/alr.23079
3. Eisenberg D, Shikora SA, Aarts E, et al. 2022 American Society for Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO): indications for metabolic and bariatric surgery. *Obes Surg*. 2023;33(1):3-14. doi:10.1007/s11695-022-06332-1
4. Gottlieb DJ, Punjabi NM. Diagnosis and management of obstructive sleep apnea: a review. *JAMA*. 2020;323(14):1389-1400. doi:10.1001/jama.2020.3514
5. Kim DH, Kim SW, Han JS, et al. Hypoglossal nerve stimulation effects on obstructive sleep apnea over time: a systematic review and meta-analysis. *Otolaryngol Head Neck Surg*. 2024;170(3):736-746. doi:10.1002/ohn.617
6. Mashaqi S, Patel SI, Combs D, et al. The hypoglossal nerve stimulation as a novel therapy for treating obstructive sleep apnea – a literature review. *Int J Environ Res Public Health*. 2021;18(4):1642. doi:10.3390/ijerph18041642
7. Olson MD, Junna MR. Hypoglossal nerve stimulation therapy for the treatment of obstructive sleep apnea. *Neurotherapeutics*. 2021;18(1):91-99. doi:10.1007/s13311-021-01012-x
8. Position statement: hypoglossal nerve stimulation for treatment of obstructive sleep apnea (OSA). American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS). Revised April 22, 2021. Accessed November 12, 2024. www.entnet.org
9. Schwartz AR, Jacobowitz O, Eisele DW, et al. Targeted hypoglossal nerve stimulation for patients with obstructive sleep apnea: a randomized clinical trial. *JAMA Otolaryngol Head Neck Surg*. 2023;149(6):512-520. doi:10.1001/jamaoto.2023.0161
10. Suurna M. Hypoglossal nerve stimulation for adult patients with obstructive sleep

The MEDICAL Policy Statement detailed above has received due consideration as defined in the MEDICAL Policy Statement Policy and is approved.

apnea. UpToDate. Updated May 28, 2024. Accessed November 12, 2024.
www.uptodate.com

11. Tietjens JR, Claman D, Kezirian EJ, et al. Obstructive sleep apnea in cardiovascular disease: a review of the literature and proposed multidisciplinary clinical management strategy. *J Am Heart Assoc.* 2019;8(1):e010440. doi:10.1161/JAHA.118.010440
12. Yeghiazarians Y, Jneid H, Tietjens JR, et al. Obstructive sleep apnea and cardiovascular disease: a scientific statement from the American Heart Association. *Circulation.* 2021;144(3):e56-e67. doi:10.1161/CIR.0000000000000988

Independent medical review – February 2022

ODM Approved 12/12/2024

The MEDICAL Policy Statement detailed above has received due consideration as defined in the MEDICAL Policy Statement Policy and is approved.